Kanzo
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
Search
Advanced search
OR
Browse
Search
Volume 46, Issue 8
Displaying 1-11 of 11 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Feature Articles
Original Article
  • The Usefulness of Combination Treatment with Interferon β Administered Twice-daily Followed by Interferon α-2b plus Ribavirin in Chronic Hepatitis C
    Yoshihisa SATO, Naohiro KAWAMURA, Shuhei OKUYAMA, Kazuhisa NAKAMURA, H ...
    Article type: Original Article
    2005 Volume 46 Issue 8 Pages 498-505
    Published: 2005
    Released on J-STAGE: November 24, 2006
    DOIhttps://doi.org/10.2957/kanzo.46.498
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Patients with chronic hepatitis C who have high viral titers are considered refractory to treatment by interferon alone. We reported the usefulness of interferon β administered twice-daily followed by interferon α treatment for high viral titer patients resulting in a high negativity rate of HCV-RNA at the early phase. We also reported the usefulness of combination treatment with interferon β administered twice-daily followed by interferon α-2b plus ribavirin at four weeks of treatment. This study reports sustained virological response to interferon β and α-2b plus ribavirin treatment. In genotype 1b patients, the rate of sustained virological response was 44.4% (12/27) after six months. In genotype 1b and over 500 kIU/ml, the rate of sustained viral response was 31.6% (6/19). In genotype non 1b patients, the rate of sustained viral response was 86.7% (13/15). Multivariate analysis of factors potentially associated with sustained virological response was only HCV-RNA negativity at 4 weeks of treatment. This treatment was extremely useful for high viral titer patients with chronic hepatitis C because of the high negativity rate of HCV-RNA at the early phase and the effects by interferon α-2b plus ribavirin at the late phase.
    View full abstract
    Download PDF (711K)
Case Reports
  • Administration of lamivudine for chronic hepatitis resulting from acute HBV genotype A infection
    Noritaka WAKUI, Koji ISHII, Katuya HIGAMI, Mie SHINOHARA, Takashi IKEH ...
    Article type: Case Report
    2005 Volume 46 Issue 8 Pages 506-511
    Published: 2005
    Released on J-STAGE: November 24, 2006
    DOIhttps://doi.org/10.2957/kanzo.46.506
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    In April 2002, a 52-year-old male was admitted to our hospital for HBs antigen-positive hepatopathy. Liver biopsy suggested chronic hepatitis. Before 2001, the patient had been negative for HBs antigen, and the transaminase level had been normal. Therefore, we considered that HB virus-related acute hepatitis had become a chronic condition. In this patient, the HBV genotype was evaluated as type A. After diagnosis, oral administration of lamivudine at 100 mg/day was started. After 5 months of treatment, the HBV-DNA level had decreased to 2.6 Log copies/ml. After 7 months, the ALT level had normalized, and remained within the normal range thereafter. After 11 months, the patient became negative for HBs antigen ; however, there was no HBs antibody. After 14 months, oral administration of lamivudine was discontinued. Thereafter, the ALT level was within the normal range, and the HBV-DNA level was below the detection sensitivity. We report a patient in whom oral administration of lamivudine was effective for acute HBV genotype A infection led to a chronic condition.
    View full abstract
    Download PDF (717K)
  • A case of acute hepatitis E virus infection with clinical features indistinguishable from drug-induced liver injury
    Masaya IWAMURO, Mitsuhiko KAWAGUCHI, Ryo TERADA, Toshiya OHSAWA, Kazuh ...
    Article type: Case Report
    2005 Volume 46 Issue 8 Pages 512-515
    Published: 2005
    Released on J-STAGE: November 24, 2006
    DOIhttps://doi.org/10.2957/kanzo.46.512
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We experienced a case of acute hepatitis E virus (HEV) infection with clinical features indistinguishable from drug-induced liver injury. A 71-year old female was admitted to the hospital because of an elevation of serum trasnaminase levels. Kampo medicines had been administered four weeks before, and lymphocyte stimulation tests for Kampo medicines were positive. In consequence, we assumed that drug-induced reaction was the cause of her liver injury. Afterward, however, both immunoglobulin M antibodies against HEV and HEV RNA turned out to be positive. Finally, we diagnosed as acute HEV infection. The patient had no history of a travel abroad, ingestion of a wild boar, deer or goat. She had eaten a pig liver one month before, which was presumed as a source of infection.
    View full abstract
    Download PDF (348K)
  • A case report of septic metastatic meningitis from Klebsiella pneumoniae liver abscess after hepaticojejunostomy for bile duct cancer
    Susumu TAKAMATSU, Norio NOGUCHI, Daisuke BAN, Takahiro SANADA, Atsushi ...
    Article type: Case Report
    2005 Volume 46 Issue 8 Pages 516-522
    Published: 2005
    Released on J-STAGE: November 24, 2006
    DOIhttps://doi.org/10.2957/kanzo.46.516
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A 63-year-old female who underwent bile duct resection with hepaticojejunostomy for bile duct cancer on August 2004 was admitted on November 2004 because of a liver abscess due to the postoperative reflux cholangitis. We performed the percutaneous transhepatic abscess drainage, and the Klebsiella pneumoniae was identified from the cultures of both arterial blood and the purulent discharge from the liver abscess. She had consciousness disturbance and neck stiffness three days after admission. The septic metastatic bacterial meningitis due to K. pneumoniae liver abscess was confirmed with the increasing of cell count of the cerebrospinal fluid (CSF) and the detection of K. pneumoniae from CFS. Although both liver abscess and meningitis were improved by the percutaneous drainage and the administration of the antibiotics for eight weeks, the normal pressure hydrocephalus that was a sequela of the meningitis was occurred and the ventriculoperitoneal shunt was necessary to relieve the symptoms.
    View full abstract
    Download PDF (1030K)
Rapid Communication
  • A novel entecavir-resistant virus with patient of lamivudine-resistant hepatitis B virus mutant
    F Suzuki, Y Suzuki, N Akuta, T Hosaka, H Sezaki, T Someya, M Kobayashi ...
    Article type: Rapid Communication
    2005 Volume 46 Issue 8 Pages 523
    Published: 2005
    Released on J-STAGE: November 24, 2006
    DOIhttps://doi.org/10.2957/kanzo.46.523
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine-resistant hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, one patient for whom previous therapies had failed exhibited virologic breakthrough while on ETV. Isolates from this patient were analyzed genotypically for emergent substitutions in HBV reverse transcriptase (RT). After 135 weeks of lamivudine therapy, patient received 0.5 mg of ETV for 52 weeks followed by 1.0 mg of ETV continuously. Viral rebound occurred at 84 weeks after ETV was started. The lamivudine RT substitutions rtH55R, rtL180M and rtM204V were present at study entry, and the additional substitutions rtS202G and rtL269I emerged during ETV treatment.
    View full abstract
    Download PDF (284K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top